David Smith
Directeur/Membre du Conseil chez IO BIOTECH, INC.
Fortune : 326 406 $ au 30/04/2024
Profil
David V.
Smith currently holds positions as an Independent Director at Codexis, Inc., a Director at Neurelis, Inc., a Director at Acepodia Biotechnologies, Ltd., an Independent Director at IO Biotech, Inc., and a Strategic Advisor at Monterey Innovation Acquisition Corp.
Previously, he held positions as a Director at Perlegen Sciences, Inc., CFO, Principal Accounting Officer, VP & Controller at Chiron Corp., Principal at Genentech, Inc., Chief Financial Officer & Vice President-Finance at Anergen, Inc., Chief Financial Officer & Executive Vice President at Thoratec Corp., Chief Financial Officer & Executive Vice President at Five Prime Therapeutics, Inc., and Chief Operating Officer at IntegenX, Inc. He also served as an Independent Director at OncoGenex Pharmaceuticals, Inc. Mr. Smith earned an MBA degree from Golden Gate University in 1987 and an undergraduate degree from Willamette University in 1981.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CODEXIS, INC.
0,18% | 18/04/2024 | 123 172 ( 0,18% ) | 326 406 $ | 30/04/2024 |
IO BIOTECH, INC.
-.--% | 08/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de David Smith
| Sociétés | Poste | Début |
|---|---|---|
| CODEXIS, INC. | Directeur/Membre du Conseil | 01/03/2016 |
| MONTEREY INNOVATION ACQUISITION CORP. | Corporate Officer/Principal | - |
| IO BIOTECH, INC. | Directeur/Membre du Conseil | 01/03/2022 |
Neurelis, Inc.
 Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 18/10/2021 |
Acepodia Biotechnologies, Ltd.
 Acepodia Biotechnologies, Ltd. BiotechnologyHealth Technology Acepodia Biotechnologies, Ltd. engages in the development of cell therapies to treat patients with cancers. Its business information includes biotechnology service industry, intellectual property rights, and wholesale and retail trade of chemical raw materials. The company was founded by Patrick Yang, and by Sonny Hsiao on June 19, 2017 and is headquartered in Taipei, Taiwan. | Directeur/Membre du Conseil | 06/01/2022 |
Anciens postes connus de David Smith
| Sociétés | Poste | Fin |
|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Directeur Financier/CFO | 16/04/2021 |
IntegenX, Inc.
 IntegenX, Inc. BiotechnologyHealth Technology IntegenX, Inc. develops rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products. The firm platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics and biodefense applications. The company was founded by Stevan Jovanovich, Dennis W. Harris, Richard A. Mathies in 2003 and is headquartered in Pleasanton, CA. | Directeur des opérations | 01/03/2018 |
| THORATEC CORPORATION | Directeur Financier/CFO | 01/07/2011 |
Perlegen Sciences, Inc.
 Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Perlegen Sciences, Inc. discovers and develops drugs. Its product pipeline consists of targeted drug candidates addressing type II diabetes and dyslipidemia markets. The company's products include PGX-510 and PGX-520. It operates in the United States, European Union, and Japan. Perlegen Sciences was co-founded by Brad A. Margus, David R. Cox, and Stephen P. A. Fodor in 2000 and is headquartered in Mountain View, CA | Directeur/Membre du Conseil | 01/10/2009 |
| ░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de David Smith
| Golden Gate University | Masters Business Admin |
| Willamette University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| IBM | Technology Services |
| CODEXIS, INC. | Process Industries |
| IO BIOTECH, INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Perlegen Sciences, Inc.
Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Perlegen Sciences, Inc. discovers and develops drugs. Its product pipeline consists of targeted drug candidates addressing type II diabetes and dyslipidemia markets. The company's products include PGX-510 and PGX-520. It operates in the United States, European Union, and Japan. Perlegen Sciences was co-founded by Brad A. Margus, David R. Cox, and Stephen P. A. Fodor in 2000 and is headquartered in Mountain View, CA | Retail Trade |
Thoratec Corp.
 Thoratec Corp. Medical SpecialtiesHealth Technology Thoratec Corp. develops, manufactures and markets proprietary medical devices used for circulatory support for the treatment of heart failure patients. The company's products include Ventricular Assist Devices, HeartMate Left Ventricular Assist System, HeartMate II Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device and Thoratec Implantable Ventricular Assist. It also manufactures and markets the CentriMag Acute Circulatory System, HeartMate II, PVAD, IVAD and for pediatric patients PediMag/PediVAS Acute Circulatory System. Its ventricular assist devices products primarily serve patients suffering from late-stage heart failure. Heart Failure is a chronic disease that occurs when degeneration of the heart muscle reduces the pumping power of the heart, causing the heart to become too weak to pump blood at a level sufficient to meet the body's demands. The company operates its business through the Cardiovascular group segment, which develops, manufactures mechanical circulatory products to support the cardiovascular systems of humans and to provide product-related services. Thoratec was founded in March 1976 and is headquartered in Pleasanton, CA. | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| Syntex Corp. | Health Technology |
| Anergen, Inc. | Health Technology |
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Health Technology |
IntegenX, Inc.
IntegenX, Inc. BiotechnologyHealth Technology IntegenX, Inc. develops rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products. The firm platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce products for DNA-based human identity testing and forensics and biodefense applications. The company was founded by Stevan Jovanovich, Dennis W. Harris, Richard A. Mathies in 2003 and is headquartered in Pleasanton, CA. | Health Technology |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Monterey Innovation Acquisition Corp.
 Monterey Innovation Acquisition Corp. Financial ConglomeratesFinance Monterey Innovation Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on July 23, 2020 and is headquartered in New York, NY. | Finance |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | Health Technology |
Acepodia Biotechnologies, Ltd.
Acepodia Biotechnologies, Ltd. BiotechnologyHealth Technology Acepodia Biotechnologies, Ltd. engages in the development of cell therapies to treat patients with cancers. Its business information includes biotechnology service industry, intellectual property rights, and wholesale and retail trade of chemical raw materials. The company was founded by Patrick Yang, and by Sonny Hsiao on June 19, 2017 and is headquartered in Taipei, Taiwan. | Health Technology |
